Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400965 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
A Phase 2 study of Demodex Blepharitis, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT07400965 is a Phase 2 study of Demodex Blepharitis that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07400965, a Phase 2 study of Demodex Blepharitis, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Conditions Studied
Interventions
- DRUG GLK-321 low dose BID
- DRUG GLK-321 mid dose BID
- DRUG GLK-321 high dose BID
- DRUG GLK-321 high dose QD
- DRUG Placebo BID
Study Locations (1)
California
- Glaukos Clinical Study Site - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07400965
The ClinicalTrials.gov registry entry for NCT07400965 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Demodex Blepharitis appearing as the primary indexed condition, and to 5 interventions - of which GLK-321 low dose BID is the first listed.
NCT07400965 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07400965 about?
NCT07400965 is a clinical study titled "Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis". This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
What is the current status of trial NCT07400965?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-12-05. Estimated completion is 2026-11.
What conditions does trial NCT07400965 study?
This clinical trial studies the following conditions: Demodex Blepharitis.
What interventions are being tested in trial NCT07400965?
The interventions under investigation include: GLK-321 low dose BID (DRUG), GLK-321 mid dose BID (DRUG), GLK-321 high dose BID (DRUG), GLK-321 high dose QD (DRUG), Placebo BID (DRUG).
Who is sponsoring clinical trial NCT07400965?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400965 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Demodex Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.